PHASE-II STUDY OF CISPLATIN, MAYTANSINE, AND CHLOROZOTOCIN IN SMALL CELL LUNG-CARCINOMA (EST-2578)

  • 1 January 1982
    • journal article
    • research article
    • Vol. 66  (6) , 1417-1419
Abstract
Seventy-three patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of cisplatin, maytansine and chlorozotocin. Of the 58 evaluable patients, only 1 partial response was observed among 21 patients given cisplatin; no responses were seen among 19 given maytansine or 18 given chlorozotocin. One patient treated with chlorozotocin and 2 treated with cisplatin experienced life-threatening thrombocytopenia. One-third of the maytansine-treated patients experienced moderate or severe neurologic toxicity. The overall median survival was 9.7 wk. Chlorozotocin treatment was associated with inferior survival (7.7 wk).

This publication has 0 references indexed in Scilit: